598 related articles for article (PubMed ID: 32372202)
1. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
Adeniji AA; Knoll KE; Loots DT
Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
[TBL] [Abstract][Full Text] [Related]
2. Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.
Alghamdi S; Rehman SU; Shesha NT; Faidah H; Khurram M; Rehman SU
Molecules; 2020 Dec; 25(23):. PubMed ID: 33276545
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
5. Synthetic investigational new drugs for the treatment of tuberculosis.
Kwon YS; Koh WJ
Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
[TBL] [Abstract][Full Text] [Related]
6. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
7. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP
Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660
[TBL] [Abstract][Full Text] [Related]
9. Management of drug resistantTB in patients with HIV co-infection.
Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
Fatima S; Bhaskar A; Dwivedi VP
Front Immunol; 2021; 12():645485. PubMed ID: 33927718
[TBL] [Abstract][Full Text] [Related]
11. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
[TBL] [Abstract][Full Text] [Related]
12. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Poce G; Cocozza M; Consalvi S; Biava M
Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
[TBL] [Abstract][Full Text] [Related]
13. Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis.
Rollo RF; Mori G; Hill TA; Hillemann D; Niemann S; Homolka S; Fairlie DP; Blumenthal A
Microbiol Spectr; 2023 Aug; 11(4):e0046523. PubMed ID: 37289062
[TBL] [Abstract][Full Text] [Related]
14. TMC207 becomes bedaquiline, a new anti-TB drug.
Palomino JC; Martin A
Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
[TBL] [Abstract][Full Text] [Related]
15. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
17. A review of recent advances in anti-tubercular drug development.
Umumararungu T; Mukazayire MJ; Mpenda M; Mukanyangezi MF; Nkuranga JB; Mukiza J; Olawode EO
Indian J Tuberc; 2020 Oct; 67(4):539-559. PubMed ID: 33077057
[TBL] [Abstract][Full Text] [Related]
18. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
19. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.
Palomino JC; Martin A
Future Microbiol; 2016; 11(4):539-47. PubMed ID: 27070731
[TBL] [Abstract][Full Text] [Related]
20. Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use".
Amaral L; Molnar J
Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):109-14. PubMed ID: 20156179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
